142 related articles for article (PubMed ID: 27771183)
1. Manufacturing costs of HPV vaccines for developing countries.
Clendinen C; Zhang Y; Warburton RN; Light DW
Vaccine; 2016 Nov; 34(48):5984-5989. PubMed ID: 27771183
[TBL] [Abstract][Full Text] [Related]
2. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
3. Mathematical models of cervical cancer prevention in the Asia Pacific region.
Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
[TBL] [Abstract][Full Text] [Related]
4. Implementation of human papillomavirus immunization in the developing world.
Kane MA; Serrano B; de Sanjosé S; Wittet S
Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
[TBL] [Abstract][Full Text] [Related]
5. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
7. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
8. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of HPV vaccination in Belize.
Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
[TBL] [Abstract][Full Text] [Related]
10. Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries.
Campos NG; Sharma M; Clark A; Kim JJ; Resch SC
PLoS One; 2016; 11(10):e0164000. PubMed ID: 27711124
[TBL] [Abstract][Full Text] [Related]
11. The patent buyout price for human papilloma virus (HPV) vaccine and the ratio of R&D costs to the patent value.
Songane M; Grossmann V
PLoS One; 2021; 16(1):e0244722. PubMed ID: 33428667
[TBL] [Abstract][Full Text] [Related]
12. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
Crager SE; Guillen E; Price M
Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
[TBL] [Abstract][Full Text] [Related]
13. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
Goldie SJ; O'Shea M; Diaz M; Kim SY
Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
[TBL] [Abstract][Full Text] [Related]
14. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
15. Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries.
Ochalek J; Abbas K; Claxton K; Jit M; Lomas J
BMJ Glob Health; 2020 Oct; 5(10):. PubMed ID: 33082132
[TBL] [Abstract][Full Text] [Related]
16. Costs of vaccine programs across 94 low- and middle-income countries.
Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
[TBL] [Abstract][Full Text] [Related]
17. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus vaccine trials and tribulations: Vaccine efficacy.
Handler NS; Handler MZ; Majewski S; Schwartz RA
J Am Acad Dermatol; 2015 Nov; 73(5):759-67; quiz 767-8. PubMed ID: 26475535
[TBL] [Abstract][Full Text] [Related]
19. HPV & HPV vaccination: issues in developing countries.
Bharadwaj M; Hussain S; Nasare V; Das BC
Indian J Med Res; 2009 Sep; 130(3):327-33. PubMed ID: 19901442
[TBL] [Abstract][Full Text] [Related]
20. The Australian experience with the human papillomavirus vaccine.
Garland SM
Clin Ther; 2014 Jan; 36(1):17-23. PubMed ID: 24417782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
